Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications
Newer obesity medications cost substantially more than generic alternatives without demonstrating superior healthcare outcomes in the first three years.
A large real-world claims study (n=228,654) found that newer GLP-1RA obesity medications are substantially more expensive without demonstrating significantly better health care utilization patterns compared to generic phentermine in the first 3 years post-initiation. This raises cost-effectiveness concerns relevant to healthcare policy and insurance coverage decisions for obesity pharmacotherapy.
What the study was
- Study design
- Retrospective comparative cohort study (commercial claims data)
- Population
- New initiators of phentermine (n=136,788), phentermine-topiramate-ER (n=13,888), naltrexone-bupropion-SR (n=28,712), or liraglutide (n=49,266) for obesity
- Sample size
- 228654
- Category
- Public Health
- Maturity
- Validated
- Journal
- Obesity
Why it surfaced
Large real-world study (n=228K) on obesity medication costs; relevant policy context for GLP-1RA landscape. Does not assess newer weekly GLP-1RAs (tirzepatide/semaglutide).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.